Structure analysis reveals the flexibility of the ADAMTS-5 active site |
| |
Authors: | Shieh Huey-Sheng Tomasselli Alfredo G Mathis Karl J Schnute Mark E Woodard Scott S Caspers Nicole Williams Jennifer M Kiefer James R Munie Grace Wittwer Arthur Malfait Anne-Marie Tortorella Micky D |
| |
Institution: | 1Pfizer Global Research and Development, St. Louis, Missouri 63017;2Rush Medical Center, Chicago, Illinois 60612;3Guangzhou Institutes of Biomedicine and Health, Guangzhou, China 510530 |
| |
Abstract: | A ((1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl) succinamide derivative (here referred to as Compound 12) shows significant activity toward many matrix metalloproteinases (MMPs), including MMP-2, MMP-8, MMP-9, and MMP-13. Modeling studies had predicted that this compound would not bind to ADAMTS-5 (a disintegrin and metalloproteinase with thrombospondin motifs-5) due to its shallow S1' pocket. However, inhibition analysis revealed it to be a nanomolar inhibitor of both ADAMTS-4 and -5. The observed inconsistency was explained by analysis of crystallographic structures, which showed that Compound 12 in complex with the catalytic domain of ADAMTS-5 (cataTS5) exhibits an unusual conformation in the S1' pocket of the protein. This first demonstration that cataTS5 can undergo an induced conformational change in its active site pocket by a molecule like Compound 12 should enable the design of new aggrecanase inhibitors with better potency and selectivity profiles. |
| |
Keywords: | aggrecanase ADAMTS metalloprotease osteoarthritis |
本文献已被 PubMed 等数据库收录! |
|